Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

This study investigated the activity of lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Lenalidomide was given at 10 mg daily with dose escalation up to 25 mg daily. Three patients (7%) achieved a complete response (CR), one a nodular partial remission, and 10 p...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Ferrajoli, Alessandra, Lee, Bang-Ning, Schlette, Ellen J., O'Brien, Susan M., Gao, Hui, Wen, Sijin, Wierda, William G., Estrov, Zeev, Faderl, Stefan, Cohen, Evan N., Li, Changping, Reuben, James M., Keating, Michael J.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2008
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4082321/
https://ncbi.nlm.nih.gov/pubmed/18334676
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-12-130120
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky